Forside  
Velg data du ønsker med i utskriften
Tittel Versjon Status
IS-nr ISBN
Revisjonsdato Publiseringsdato
Utgiver(e) Redaktør Publikasjonstype
  • Norsk tittel - Nasjonale retningslinjer for diagnostikk, behandling og oppfølging av nyrecellekreft
  • Engelsk tittel -
  • Versjon - 1
  • Status - Publisert
  • IS-nr - 2364
  • ISBN - 978-82-8081-407-4
  • DOI -
  • Revisjonsdato - 03.09.2015
  • Neste revisjon -
  • Publikasjonsdato - 01.06.2007
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør - Overlege PhD Christian Beisland m.fl.
  • Publikasjonstype - Nasjonale retningslinjer
Vedlegg
 
  1. Cancer in Norway 2001. Oslo: Cancer Registry of Norway; 2004.
  2. II Svulster i alt (C00-D48) 2005. ICD-10 Dødsårsak etter detaljert internasjonal liste Statistisk sentralbyrå [oppdatert 2008; lest 27 May 2005]. Tilgjengelig fra: http://www.ssb.no/emner/03/01/10/dodsarsak/kap-ii-c00-d48.html
  3. European Association of Urology. Guidelines on Renal Cell Carcinoma. I: Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PFA PJ, Sinecu IC, red. EAU; 2007.
  4. Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg 2004;93(2):88-96. Tilgjengelig fra: PM:15285559
  5. Patard JJ, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Prognostic significance of the mode of detection in renal tumours. Bju International 2002;90(4):358-63. Tilgjengelig fra: ISI:000177440100002
  6. Tsui KH, Shvarts O, Smith RB, Figlin R, deKernion JB, Belldegrun A. Renal cell carcinoma: Prognostic significance of incidentally detected tumors. Journal of Urology 2000;163(2):426-30. Tilgjengelig fra: ISI:000084765900006
  7. Beisland C, Medby PC, Beisland HO. Renal cell carcinoma: gender difference in incidental detection and cancer-specific survival. Scand J Urol Nephrol 2002;36(6):414-8. Tilgjengelig fra: PM:12623504
  8. Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol 2004;172(3):863-6. Tilgjengelig fra: PM:15310984
  9. IARC: http://www-cie.iarc.fr/htdocs/monographs/vol83/01-smoking.html [E-mail]. Sendt til 2005 Sep 5 [sitert
  10. Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281(17):1628-31. Tilgjengelig fra: PM:10235157
  11. Vaishampayan UN, Do H, Hussain M, Schwartz K. Racial disparity in incidence patterns and outcome of kidney cancer. Urology 2003;62(6):1012-7. Tilgjengelig fra: PM:14665346
  12. Chauveau D, Duvic C, Chretien Y, Paraf F, Droz D, Melki P, et al. Renal involvement in von Hippel-Lindau disease. Kidney International 1996;50(3):944-51. Tilgjengelig fra: ISI:A1996VD76600026
  13. Zbar B, Glenn G, Lubensky I, Choyke P, Walther MM, Magnusson G, et al. Hereditary Papillary Renal-Cell Carcinoma - Clinical-Studies in 10 Families. Journal of Urology 1995;153(3):907-12. Tilgjengelig fra: ISI:A1995QF63400005
  14. Toro JR, Glenn G, Duray P, Darling T, Weirich G, Zbar B, et al. Birt-Hogg-Dube syndrome - A novel marker of kidney neoplasia. Archives of Dermatology 1999;135(10):1195-202. Tilgjengelig fra: ISI:000083036400005
  15. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999;354(9173):93-9. Tilgjengelig fra: PM:10408483
  16. Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003;14(1):197-207. Tilgjengelig fra: PM:12506152
  17. McLaughlin JK, Lindblad P, Mellemgaard A, McCredie M, Mandel JS, Schlehofer B, et al. International Renal-Cell Cancer Study .1. Tobacco Use. International Journal of Cancer 1995;60(2):194-8. Tilgjengelig fra: ISI:A1995QH51800010
  18. Talamini R, Baron AE, Barra S, Bidoli E, La Vecchia C, Negri E, et al. A case-control study of risk factor for renal cell cancer in northern Italy. Cancer Causes Control 1990;1(2):125-31. Tilgjengelig fra: PM:2102282
  19. Chiu BC, Lynch CF, Cerhan JR, Cantor KP. Cigarette smoking and risk of bladder, pancreas, kidney, and colorectal cancers in Iowa. Ann Epidemiol 2001;11(1):28-37. Tilgjengelig fra: PM:11164117
  20. Bjorge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. American Journal of Epidemiology 2004;160(12):1168-76. Tilgjengelig fra: ISI:000225663600006
  21. Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer - a quantitative review. British Journal of Cancer 2001;85(7):984-90. Tilgjengelig fra: ISI:000171685300010
  22. Pischon T, Lahmann PH, Boeing H, Tjonneland A, Halkjaer J, Overvad K, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006;118(3):728-38. Tilgjengelig fra: PM:16094628
  23. Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urologic Oncology 2002;7(4):135-40. Tilgjengelig fra: ISI:000177052600002
  24. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998;51(2):203-5. Tilgjengelig fra: PM:9495698
  25. Homma Y, Kawabe K, Kitamura T, Nishimura Y, Shinohara M, Kondo Y, et al. Increased incidental detection and reduced mortality in renal cancer--recent retrospective analysis at eight institutions. Int J Urol 1995;2(2):77-80. Tilgjengelig fra: PM:7553292
  26. Beisland C, Medby PC, Beisland HO. [Renal cancer--a retrospective study of 368 patients]. Tidsskr Nor Laegeforen 2002;122(25):2431-5. Tilgjengelig fra: PM:12448109
  27. Pantuck AJ, Zisman A, Rauch MK, Belldegrun A. Incidental renal tumors. Urology 2000;56(2):190-6. Tilgjengelig fra: PM:10925076
  28. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649-55. Tilgjengelig fra: PM:7165009
  29. Baldwin DD, Dunbar JA, Parekh DJ, Wells N, Shuford MD, Cookson MS, et al. Single-center comparison of purely laparoscopic, hand-assisted laparoscopic, and open radical nephrectomy in patients at high anesthetic risk. Journal of Endourology 2003;17(3):161-7. Tilgjengelig fra: ISI:000182535300005
  30. Han KR, Kim HL, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun AS. Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology 2004;63(5):841-6. Tilgjengelig fra: PM:15134960
  31. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scandinavian Journal of Urology and Nephrology 2000;34(4):246-51. Tilgjengelig fra: ISI:000089681900004
  32. Citterio G, Bertuzzi A, Tresoldi M, Galli L, DiLucca G, Scaglietti U, et al. Prognostic factors for survival in metastatic renal cell carcinoma: Retrospective analysis from 109 consecutive patients. European Urology 1997;31(3):286-91. Tilgjengelig fra: ISI:A1997WU39500005
  33. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2004;22(3):454-63. Tilgjengelig fra: ISI:000188738900012
  34. Herts BR, Coll DM, Lieber ML, Streem SB, Novick AC. Triphasic helical CT of the kidneys: Contribution of vascular phase scanning in patients before urologic surgery. American Journal of Roentgenology 1999;173(5):1273-7. Tilgjengelig fra: ISI:000083312300026
  35. Bechtold RE, Zagoria RJ. Imaging approach to staging of renal cell carcinoma. Urol Clin North Am 1997;24(3):507-22. Tilgjengelig fra: PM:9275976
  36. Coll DM, Uzzo RG, Herts BR, Davros WJ, Wirth SL, Novick AC. 3-dimensional volume rendered computerized tomography for preoperative evaluation and intraoperative treatment of patients undergoing nephron sparing surgery. Journal of Urology 1999;161(4):1097-102. Tilgjengelig fra: ISI:000079014000010
  37. Ueda T, Tobe T, Yamamoto S, Motoori K, Murakami Y, Igarashi T, et al. Selective intra-arterial 3-dimensional computed tomography angiography for preoperative evaluation of nephron-sparing surgery. Journal of Computer Assisted Tomography 2004;28(4):496-504. Tilgjengelig fra: ISI:000222861400010
  38. Heidenreich A, Ravery V. Preoperative imaging in renal cell cancer. World Journal of Urology 2004;22(5):307-15. Tilgjengelig fra: ISI:000226553600002
  39. Sheth S, Scatarige JC, Horton KM, Corl FM, Fishman EK. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT. Radiographics 2001;21 Spec No:S237-S254. Tilgjengelig fra: PM:11598260
  40. Lim DJ, Carter MF. Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. J Urol 1993;150(4):1112-4. Tilgjengelig fra: PM:8371366
  41.     41.   Roy C, Buy X, el Ghali S. Imaging in Renal Cell Cancer. EAU Updates Series 2003;1:209-14.
  42. Munro NP, Woodhams S, Nawrocki JD, Fletcher MS, Thomas PJ. The role of transarterial embolization in the treatment of renal cell carcinoma. Bju International 2003;92(3):240-4. Tilgjengelig fra: ISI:000184333000015
  43. Henriksson C, Haraldsson G, Aldenborg F, Lindberg S, Pettersson S. Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma. Scand J Urol Nephrol 1992;26(4):363-6. Tilgjengelig fra: PM:1292074
  44. Bos SD, Piers DA, Mensink HJ. Routine bone scan and serum alkaline phosphatase for staging in patients with renal cell carcinoma is not cost-effective. Eur J Cancer 1995;31A(13-14):2422-3. Tilgjengelig fra: PM:8652286
  45. Blacher E, Johnson DE, Haynie TP. Value of routine radionuclide bone scans in renal cell carcinoma. Urology 1985;26(5):432-4. Tilgjengelig fra: PM:4060382
  46. Koga S, Tsuda S, Nishikido M, Ogawa Y, Hayashi K, Hayashi T, et al. The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol 2001;166(6):2126-8. Tilgjengelig fra: PM:11696720
  47. Marshall ME, Pearson T, Simpson W, Butler K, McRoberts W. Low incidence of asymptomatic brain metastases in patients with renal cell carcinoma. Urology 1990;36(4):300-2. Tilgjengelig fra: PM:2219605
  48. Brierly RD, Thomas PJ, Harrison NW, Fletcher MS, Nawrocki JD, shton-Key M. Evaluation of fine-needle aspiration cytology for renal masses. BJU Int 2000;85(1):14-8. Tilgjengelig fra: PM:10619937
  49. International Union Against Cancer. TNM - Classification of malignant tumours. 6 (2002) ed. Sobin LH., Wittekind C, editors. New York: Wiley; 2002.
  50. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005;173(6):1889-92. Tilgjengelig fra: PM:15879769
  51. Salama ME, Guru K, Stricker H, Peterson E, Peabody J, Menon M, et al. pT1 substaging in renal cell carcinoma: validation of the 2002 TNM staging modification of malignant renal epithelial tumors. J Urol 2005;173(5):1492-5. Tilgjengelig fra: PM:15821466
  52. Ficarra V, Schips L, Guille F, Li G, de la TA, Prayer GT, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer 2005;104(5):968-74. Tilgjengelig fra: PM:16007683
  53. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol 2005;174(4 Pt 1):1218-21. Tilgjengelig fra: PM:16145373
  54. Bonsib SM. The renal sinus is the principal invasive pathway: a prospective study of 100 renal cell carcinomas. Am J Surg Pathol 2004;28(12):1594-600. Tilgjengelig fra: PM:15577678
  55. Alamdari FI, Ljungberg B. Adrenal metastasis in renal cell carcinoma: A recommendation for adjustment of the TNM staging system. Scand J Urol Nephrol 2005;39(4):277-82. Tilgjengelig fra: PM:16118103
  56. Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? Journal of Urology 2005;173(3):918-21. Tilgjengelig fra: ISI:000227075500055
  57. Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, et al. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 2003;169(3):899-903. Tilgjengelig fra: PM:12576809
  58. Terrone C, Cracco C, Porpiglia F, Bollito E, Scoffone C, Poggio M, et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 2006;49(2):324-31. Tilgjengelig fra: PM:16386352
  59. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. Journal of Pathology 1997;183(2):131-3. Tilgjengelig fra: ISI:A1997YA17000003
  60. Eble JN, Sauter G, Epstein JI, Sesserhenn IA, red. Pathology an genetics of tumours of the urinary system and male genital organs. Lyon: IARCpress; 2004.
  61. Veileder i biopsibesvarelse av maligne svulster. Bostad L, editor. OSLO: Den Norske Lægeforening; 2001.
  62. Dechet CB, Sebo T, Farrow G, Blute ML, Engen DE, Zincke H. Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol 1999;162(4):1282-4. Tilgjengelig fra: PM:10492180
  63. Palapattu GS, Pantuck AJ, Dorey F, Said JW, Figlin RA, Belldegrun AS. Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. J Urol 2003;170(3):768-72. Tilgjengelig fra: PM:12913694
  64. Bonsib SM, Gibson D, Mhoon M, Greene GF. Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol 2000;24(3):451-8. Tilgjengelig fra: PM:10716160
  65. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80(5):987-9. Tilgjengelig fra: PM:9307203
  66. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27(5):612-24. Tilgjengelig fra: PM:12717246
  67. Fuhrman SA, Lasky LC, Limas C. Prognostic-Significance of Morphologic Parameters in Renal-Cell Carcinoma. American Journal of Surgical Pathology 1982;6(7):655-63. Tilgjengelig fra: ISI:A1982PQ05900007
  68. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89(3):604-14. Tilgjengelig fra: PM:10931460
  69. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 2001;32(6):590-5. Tilgjengelig fra: PM:11431713
  70. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23(12):2763-71. Tilgjengelig fra: PM:15837991
  71. Chao D, Zisman A, Pantuck AJ, Gitlitz BJ, Freedland SJ, Said JW, et al. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol 2002;167(1):71-4. Tilgjengelig fra: PM:11743278
  72. Kennedy SM, Merino MJ, Linehan WM, Roberts JR, Robertson CN, Neumann RD. Collecting duct carcinoma of the kidney. Hum Pathol 1990;21(4):449-56. Tilgjengelig fra: PM:2318486
  73. MacLennan GT, Farrow GM, Bostwick DG. Low-grade collecting duct carcinoma of the kidney: report of 13 cases of low-grade mucinous tubulocystic renal carcinoma of possible collecting duct origin. Urology 1997;50(5):679-84. Tilgjengelig fra: PM:9372874
  74. Parwani AV, Husain AN, Epstein JI, Beckwith JB, Argani P. Low-grade myxoid renal epithelial neoplasms with distal nephron differentiation. Hum Pathol 2001;32(5):506-12. Tilgjengelig fra: PM:11381369
  75. Avery RA, Harris JE, Davis CJ, Jr., Borgaonkar DS, Byrd JC, Weiss RB. Renal medullary carcinoma: clinical and therapeutic aspects of a newly described tumor. Cancer 1996;78(1):128-32. Tilgjengelig fra: PM:8646708
  76. Ficarra V, Righetti R, Martignoni G, D'Amico A, Pilloni S, Rubilotta E, et al. Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urol Int 2001;67(2):130-4. Tilgjengelig fra: PM:11490206
  77. Al Aynati M, Chen V, Salama S, Shuhaibar H, Treleaven D, Vincic L. Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Archives of Pathology & Laboratory Medicine 2003;127(5):593-6. Tilgjengelig fra: ISI:000182662200011
  78. Lang H, Lindner V, de FM, Molinie V, Letourneux H, Meyer N, et al. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: Assessment of 241 patients with > 15-year follow-up. Cancer 2005;103(3):625-9. Tilgjengelig fra: PM:15611969
  79. Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer 1995;76(12):2543-9. Tilgjengelig fra: PM:8625083
  80. Furge KA, Lucas KA, Takahashi M, Sugimura J, Kort EJ, Kanayama HO, et al. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 2004;64(12):4117-21. Tilgjengelig fra: PM:15205321
  81. Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004;10(18 Pt 2):6282S-9S. Tilgjengelig fra: PM:15448018
  82. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res 2005;65(13):5628-37. Tilgjengelig fra: PM:15994935
  83. Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol 2004;171(5):1810-3. Tilgjengelig fra: PM:15076282
  84. Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003;170(5):1742-6. Tilgjengelig fra: PM:14532767
  85. Patard JJ, Leray E, Cindolo L, Ficarra V, Rodriguez A, de la TA, et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol 2004;172(3):858-62. Tilgjengelig fra: PM:15310983
  86. Patard JJ, Dorey FJ, Cindolo L, Ficarra V, de la TA, Tostain J, et al. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol 2004;172(6 Pt 1):2167-71. Tilgjengelig fra: PM:15538224
  87. Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guille F, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 2006;175(3 Pt 1):859-63. Tilgjengelig fra: PM:16469566
  88. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001;166(1):63-7. Tilgjengelig fra: PM:11435824
  89. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. Journal of Clinical Oncology 2001;19(6):1649-57. Tilgjengelig fra: ISI:000167652500008
  90. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168(6):2395-400. Tilgjengelig fra: PM:12441925
  91. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials. Cancer 2003;97(7):1663-71. Tilgjengelig fra: ISI:000181816600010
  92. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 2006;3(1):e13. Tilgjengelig fra: PM:16318415
  93. Robson CJ, Churchill BM, Anderson W. Results of Radical Nephrectomy for Renal Cell Carcinoma. Journal of Urology 1969;101(3):297-&. Tilgjengelig fra: ISI:A1969C711700011
  94. Makhoul B, De La TA, Vordos D, Salomon L, Sebe P, Audet JF, et al. Laparoscopic radical nephrectomy for T1 renal cancer: the gold standard? A comparison of laparoscopic vs open nephrectomy. BJU Int 2004;93(1):67-70. Tilgjengelig fra: PM:14678371
  95. Wille AH, Roigas J, DeGer S, Tullmann M, Turk I, Loening SA. Laparoscopic radical nephrectomy: techniques, results and oncological outcome in 125 consecutive cases. Eur Urol 2004;45(4):483-8. Tilgjengelig fra: PM:15041113
  96. von Knobloch R, Seseke F, Riedmiller H, Grone HJ, Walthers EM, Kalble T. Radical nephrectomy for renal cell carcinoma: Is adrenalectomy necessary? European Urology 1999;36(4):303-8. Tilgjengelig fra: ISI:000082460400006
  97. Kuczyk M, Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol 2005;48(2):252-7. Tilgjengelig fra: PM:15936136
  98. Sandock DS, Seftel AD, Resnick MI. Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. Urology 1997;49(1):28-31. Tilgjengelig fra: PM:9000180
  99. Li GR, Soulie M, Escourrou G, Plante P, Pontonnier F. Micrometastatic adrenal invasion by renal carcinoma in patients undergoing nephrectomy. Br J Urol 1996;78(6):826-8. Tilgjengelig fra: PM:9014703
  100. O'Brien WM, Lynch JH. Adrenal metastases by renal cell carcinoma. Incidence at nephrectomy. Urology 1987;29(6):605-7. Tilgjengelig fra: PM:3576885
  101. Yokoyama H, Tanaka M. Incidence of adrenal involvement and assessing adrenal function in patients with renal cell carcinoma: Is ipsilateral adrenalectomy indispensable during radical nephrectomy? Bju International 2005;95(4):526-9. Tilgjengelig fra: ISI:000227283100016
  102. Blom JHM, van Poppel H, Marechal JM, Jacqmin D, Sylvester R, Schroder FH, et al. Radical nephrectomy with and without lymph node dissection: Preliminary results of the EORTC randomized phase III protocol 30881. European Urology 1999;36(6):570-5. Tilgjengelig fra: ISI:000083614700004
  103. Minervini A, Lilas L, Morelli G, Traversi C, Battaglia S, Cristofani R, et al. Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? Bju International 2001;88(3):169-72. Tilgjengelig fra: ISI:000170425200001
  104. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 2003;169(6):2076-83. Tilgjengelig fra: PM:12771723
  105. Joslyn SA, Sirintrapun SJ, Konety BR. Impact of lymphadenectomy and nodal burden in renal cell carcinoma: Retrospective analysis of the national surveillance, epidemiology, and end results database. Urology 2005;65(4):675-80. Tilgjengelig fra: ISI:000228557900011
  106. Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. Journal of Urology 2004;172(2):465-9. Tilgjengelig fra: ISI:000222639300009
  107. Mejean A, Vogt B, Quazza JE, Chretien Y, Dufour B. Mortality and morbidity after nephrectomy for renal cell carcinoma using a transperitoneal anterior subcostal incision. European Urology 1999;36(4):298-302. Tilgjengelig fra: ISI:000082460400005
  108. Carmignani G, Traverso P, Corbu C. Incidental splenectomy during left radical nephrectomy: Reasons and ways to avoid it. Urologia Internationalis 2001;67(3):195-8. Tilgjengelig fra: ISI:000171729400002
  109. Mejean A, Vogt B, Cazin S, Balian C, Poisson JF, Dufour B. Nephron sparing surgery for renal cell carcinoma using selective renal parenchymal clamping. Journal of Urology 2002;167(1):234-5. Tilgjengelig fra: ISI:000172726200063
  110. Nurmi MJ, Puntala PV, Tyrkko JE, Antila LE. Trans-Abdominal and Lumbar Nephrectomy for Renal Adenocarcinoma. Scandinavian Journal of Urology and Nephrology 1985;19(2):129-31. Tilgjengelig fra: ISI:A1985APR2000010
  111. Cooper CS, Cohen MB, Donovan JF. Splenectomy complicating left nephrectomy. Journal of Urology 1996;155(1):30-6. Tilgjengelig fra: ISI:A1996TJ43400008
  112. Edna TH, Vada K, Hesselberg F, Mjolnerod OK. Blood-Transfusion and Survival Following Surgery for Renal-Carcinoma. British Journal of Urology 1992;70(2):135-8. Tilgjengelig fra: ISI:A1992JJ02700004
  113. Shvarts O, Tsui KH, Smith RB, de Kernion JB, Belldegrun A. Blood loss and the need for transfusion in patients who undergo partial or radical nephrectomy for renal cell carcinoma. Journal of Urology 2000;164(4):1160-3. Tilgjengelig fra: ISI:000089229800006
  114. Stephenson AJ, Hakimi AA, Snyder ME, Russo P. Complications of radical and partial nephrectomy in a large contemporary cohort. Journal of Urology 2004;171(1):130-4. Tilgjengelig fra: ISI:000187390800030
  115. Ljungberg B, Alamdari FI, Holmberg G, Granfors T, Duchek M. Radical nephrectomy is still preferable in the treatment of localized renal cell carcinoma - A long-term follow-up study. European Urology 1998;33(1):79-85. Tilgjengelig fra: ISI:000071682600012
  116. Beisland C, Medby PC, Sander S, Beisland HO. Nephrectomy - indications, complications and postoperative mortality in 646 consecutive patients. Eur Urol 2000;37(1):58-64. Tilgjengelig fra: PM:10671787
  117. Nuttall M, Cathcart P, Van der Meulen J, Gillatt D, McIntosh G, Emberton M. A description of radical nephrectomy practice and outcomes in England: 1995-2002. Bju International 2005;96(1):58-61. Tilgjengelig fra: ISI:000229837800016
  118. Birkmeyer JD, Siewers AE, Finlayson EVA, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. New England Journal of Medicine 2002;346(15):1128-37. Tilgjengelig fra: ISI:000174880600006
  119. Thoroddsen A, Gudbjartsson T, Jonsson E, Gislason T, Einarsson GV. Operative mortality after nephrectomy for renal cell carcinoma. Scandinavian Journal of Urology and Nephrology 2003;37(6):507-11. Tilgjengelig fra: ISI:000187296700012
  120. Javidan J, Stricker HJ, Tamboli P, Amin MB, Peabody JO, Deshpande A, et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. Journal of Urology 1999;162(4):1277-81. Tilgjengelig fra: ISI:000082510700007
  121. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. Journal of Urology 2000;163(4):1090-5. Tilgjengelig fra: ISI:000085974000005
  122. Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999;84(4):405-11. Tilgjengelig fra: PM:10468753
  123. Elmore JM, Kadesky KT, Koeneman KS, Sagalowsky AI. Reassessment of the 1997 TNM classification system for renal cell carcinoma. Cancer 2003;98(11):2329-34. Tilgjengelig fra: PM:14635066
  124. Gettman MT, Blute ML, Spotts B, Bryant SC, Zincke H. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 2001;91(2):354-61. Tilgjengelig fra: PM:11180082
  125. Ficarra V, Novara G, Galfano A, Novella G, Schiavone D, Artibani W. Application of TNM, 2002 version, in localized renal cell carcinoma: is it able to predict different cancer-specific survival probability? Urology 2004;63(6):1050-4. Tilgjengelig fra: PM:15183948
  126. Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 2004;94(1):33-41. Tilgjengelig fra: PM:15217427
  127. Ficarra V, Righetti R, D'Amico A, Rubilotta E, Novella G, Malossini G, et al. Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology 2001;61(1):10-5. Tilgjengelig fra: PM:11474242
  128. Ljungberg B, Stenling R, Osterdahl B, Farrelly E, Aberg T, Roos G. Vein invasion in renal cell carcinoma: impact on metastatic behavior and survival. J Urol 1995;154(5):1681-4. Tilgjengelig fra: PM:7563321
  129. Staehler G, Brkovic D. The role of radical surgery for renal cell carcinoma with extension into the vena cava. J Urol 2000;163(6):1671-5. Tilgjengelig fra: PM:10799157
  130. Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol 2003;169(3):909-16. Tilgjengelig fra: PM:12576811
  131. Nesbitt JC, Soltero ER, Dinney CP, Walsh GL, Schrump DS, Swanson DA, et al. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Ann Thorac Surg 1997;63(6):1592-600. Tilgjengelig fra: PM:9205155
  132. Bissada NK, Yakout HH, Babanouri A, Elsalamony T, Fahmy W, Gunham M, et al. Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology 2003;61(1):89-92. Tilgjengelig fra: PM:12559273
  133. Glazer AA, Novick AC. Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol 1996;155(2):448-50. Tilgjengelig fra: PM:8558632
  134. Hayakawa M, Nakajima F, Higa I, Koyama Y, Hatano T, Osawa A. [Study on clinical courses of 7 patients undergone resection of adjacent organs in the treatment of locally extensive renal cell carcinoma]. Nippon Hinyokika Gakkai Zasshi 1995;86(7):1302-5. Tilgjengelig fra: PM:7637249
  135. Ishikura K, Yoshida N, Hasegawa M, Nomura K, Okamoto T, Tanji S, et al. [Clinical study of renal cell carcinoma invading adjacent organs]. Hinyokika Kiyo 1994;40(5):373-7. Tilgjengelig fra: PM:8023760
  136. Watanabe K, Ikado S, Hirabayashi N, Ogawa A, Tomita Y, Wajiki M. [Results of curative or non-curative nephrectomy for renal cell carcinoma invading adjacent organs]. Nippon Hinyokika Gakkai Zasshi 1992;83(8):1238-43. Tilgjengelig fra: PM:1405162
  137. Ljungberg B. Nephron-sparing surgery--strategies for partial nephrectomy in renal cell carcinoma. Scand J Surg 2004;93(2):126-31. Tilgjengelig fra: PM:15285564
  138. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol 2000;163(3):730-6. Tilgjengelig fra: PM:10687966
  139. Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: Indications, techniques and outcomes. Journal of Urology 2001;166(1):6-18. Tilgjengelig fra: ISI:000169268700001
  140. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;171(3):1066-70. Tilgjengelig fra: PM:14767272
  141. Mitchell RE, Gilbert SM, Murphy AM, Olsson CA, Benson MC, McKiernan JM. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology 2006;67(2):260-4. Tilgjengelig fra: PM:16461075
  142. Novick AC. Nephron-sparing surgery for renal cell carcinoma. Annual Review of Medicine 2002;53:393-407. Tilgjengelig fra: ISI:000174414500027
  143. Whang M, Otoole K, Bixon R, Brunetti J, Ikeguchi E, Olsson CA, et al. The Incidence of Multifocal Renal-Cell Carcinoma in Patients Who Are Candidates for Partial Nephrectomy. Journal of Urology 1995;154(3):968-70. Tilgjengelig fra: ISI:A1995RN53100011
  144. Kural AR, Demirkesen O, Onal B, Obek C, Tunc B, Onder AU, et al. Outcome of nephron-sparing surgery: elective versus imperative indications. Urol Int 2003;71(2):190-6. Tilgjengelig fra: PM:12890959
  145. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: Impact of tumorsize on patient survival, tumor recurrence and TNM staging. Journal of Urology 1999;162(6):1930-3. Tilgjengelig fra: ISI:000083639500015
  146. Van PH, Da PL, Albrecht W, Matveev V, Bono A, Borkowski A, et al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2007;51(6):1606-15. Tilgjengelig fra: PM:17140723
  147. McKiernan J, Yossepowitch O, Kattan MW, Simmons R, Motzer RJ, Reuter VE, et al. Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology 2002;60(6):1003-9. Tilgjengelig fra: PM:12475658
  148. Lundstam S, Jonsson O, Lyrdal D, Peeker R, Pettersson S. Nephron-sparing surgery for renal cell carcinoma--long-term results. Scand J Urol Nephrol 2003;37(4):299-304. Tilgjengelig fra: PM:12944187
  149. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000;75(12):1236-42. Tilgjengelig fra: PM:11126830
  150. Ono Y, Hattori R, Gotoh M, Yoshino Y, Yoshikawa Y, Kamihira O. Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already? Curr Opin Urol 2005;15(2):75-8. Tilgjengelig fra: PM:15725928
  151. Ono Y, Kinukawa T, Hattori R, Gotoh M, Kamihira O, Ohshima S. The long-term outcome of laparoscopic radical nephrectomy for small renal cell carcinoma. J Urol 2001;165(6 Pt 1):1867-70. Tilgjengelig fra: PM:11371869
  152. Permpongkosol S, Chan DY, Link RE, Jarrett TW, Kavoussi LR. Laparoscopic radical nephrectomy: Long-term outcomes. Journal of Endourology 2005;19(6):628-33. Tilgjengelig fra: ISI:000231101100012
  153. Portis AJ, Yan Y, Landman J, Chen C, Barrett PH, Fentie DD, et al. Long-term followup after laparoscopic radical nephrectomy. Journal of Urology 2002;167(3):1257-62. Tilgjengelig fra: ISI:000173752900011
  154. Goel A, Hemal AK, Gupta NP. Retroperitoneal laparoscopic radical nephrectomy and nephroureterectomy and comparison with open surgery. World Journal of Urology 2002;20(4):219-23. Tilgjengelig fra: ISI:000178335200004
  155. Dunn MD, Portis AJ, Shalhav AL, Elbahnasy AM, Heidorn C, McDougall EM, et al. Laparoscopic versus open radical nephrectomy: A 9-year experience. Journal of Urology 2000;164(4):1153-9. Tilgjengelig fra: ISI:000089229800005
  156. Abukora F, Nambirajan T, Albqami N, Leeb K, Jeschke S, Gschwendtner M, et al. Laparoscopic nephron sparing surgery: Evolution in a decade. European Urology 2005;47(4):488-93. Tilgjengelig fra: ISI:000228121500011
  157. Desai MM, Gill IS. Laparoscopic partial nephrectomy for tumour: current status at the Cleveland Clinic. Bju International 2005;95:41-5. Tilgjengelig fra: ISI:000227649200011
  158. Gill IS, Desai MM, Kaouk JH, Meraney AM, Murphy DP, Sung GT, et al. Laparoscopic partial nephrectomy for renal tumor: Duplicating open surgical techniques. Journal of Urology 2002;167(2):469-75. Tilgjengelig fra: ISI:000173212600003
  159. Novick AC. Laparoscopic and partial nephrectomy. Clinical Cancer Research 2004;10(18):6322S-7S. Tilgjengelig fra: ISI:000224080600009
  160. Gill IS, Remer EM, Hasan WA, Strzempkowski B, Spaliviero M, Steinberg AP, et al. Renal cryoablation: Outcome at 3 years. Journal of Urology 2005;173(6):1903-7. Tilgjengelig fra: ISI:000229051700014
  161. Johnson DB, Solomon SB, Su LM, Matsumoto ED, Kavoussi LR, Nakada SY, et al. Defining the complications of cryoablation and radio frequency ablation of small renal tumors: A multi-institutional review. Journal of Urology 2004;172(3):874-7. Tilgjengelig fra: ISI:000223379900014
  162. Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, et al. Percutaneous radiofrequency ablation of renal tumors: Technique, complications, and outcomes. Journal of Vascular and Interventional Radiology 2005;16(5):679-88. Tilgjengelig fra: ISI:000229058200011
  163. Gervais DA, McGovern F, Arellano RS, McDougal WS, Mueller PR. Renal cell carcinoma: Clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology 2003;226(2):417-24. Tilgjengelig fra: ISI:000180657000019
  164. Varkarakis IM, Allaf ME, Inagaki T, Bhayani SB, Chan DY, Su LM, et al. Percutaneous radio frequency ablation of renal masses: Results at a 2-year mean followup. Journal of Urology 2005;174(2):456-60. Tilgjengelig fra: ISI:000230604300013
  165. Rendon RA, Kachura JR, Sweet JM, Gertner MR, Sherar MD, Robinette M, et al. The uncertainty of radio frequency treatment of renal cell carcinoma: Findings at immediate and delayed nephrectomy. Journal of Urology 2002;167(4):1587-92. Tilgjengelig fra: ISI:000174437000003
  166. Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 1996;77(12):2560-6. Tilgjengelig fra: PM:8640706
  167. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999;17(8):2521-9. Tilgjengelig fra: PM:10561318
  168. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003;21(16):3133-40. Tilgjengelig fra: PM:12810695
  169. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005;92(5):843-6. Tilgjengelig fra: PM:15756254
  170. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363(9409):594-9. Tilgjengelig fra: PM:14987883
  171. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995;154(1):28-31. Tilgjengelig fra: PM:7776446
  172. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998;159(4):1163-7. Tilgjengelig fra: PM:9507823
  173. Beisland C, Medby PC, Beisland HO. Presumed radically treated renal cell carcinoma--recurrence of the disease and prognostic factors for subsequent survival. Scand J Urol Nephrol 2004;38(4):299-305. Tilgjengelig fra: PM:15669589
  174. Mcnichols DW, Segura JW, Deweerd JH. Renal-Cell Carcinoma - Long-Term Survival and Late Recurrence. Journal of Urology 1981;126(1):17-23. Tilgjengelig fra: ISI:A1981LZ25600005
  175. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006;24(19):3101-6. Tilgjengelig fra: PM:16809736
  176. Mickisch G, Carballido J, Hellsten S, Schuize H, Mensink H. Guidelines on renal cell cancer. European Urology 2001;40(3):252-5. Tilgjengelig fra: ISI:000172127800002
  177. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005;174(2):466-72. Tilgjengelig fra: PM:16006866
  178. Gudbjartsson T, Einarsson GV, Magnusson J. A population-based analysis of survival and incidental diagnosing of renal cell carcinoma patients in Iceland, 1971-1990. Scandinavian Journal of Urology and Nephrology 1996;30(6):451-5. Tilgjengelig fra: ISI:A1996WC01900003
  179. Leibovich BC, Han KR, Bui MHT, Pantuck AJ, Dorey FJ, Figlin RA, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma - A stratification tool for prospective clinical trials. Cancer 2003;98(12):2566-75. Tilgjengelig fra: ISI:000187018000005
  180. Fossa SD, Aass N, Tveter K, Dahl O. [Treatment of renal carcinoma with distant metastases]. Tidsskr Nor Laegeforen 2000;120(19):2274-8. Tilgjengelig fra: PM:10997087
  181. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20(9):2376-81. Tilgjengelig fra: PM:11981011
  182. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289-96. Tilgjengelig fra: PM:11773181
  183. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. New England Journal of Medicine 2001;345(23):1655-9. Tilgjengelig fra: ISI:000172517200001
  184. 184.   Mickisch GHJ, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966-70. Tilgjengelig fra: ISI:000171135300017
  185. 185.   Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J. Cytoreductive Surgery for Stage-Iv Renal-Cell Carcinoma. Journal of Urology 1995;154(1):32-4. Tilgjengelig fra: ISI:A1995RB81900011
  186. 186.   Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24. Tilgjengelig fra: PM:17215529
  187. Swanson DA. Surgery for metastases of renal cell carcinoma. Scand J Surg 2004;93(2):150-5. Tilgjengelig fra: PM:15285568
  188. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. Journal of Clinical Oncology 1998;16(6):2261-6. Tilgjengelig fra: ISI:000073919200034
  189. van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FMJ. Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. European Urology 1999;35(3):197-203. Tilgjengelig fra: ISI:000079123900004
  190. Kozlowski JM. Management of Distant Solitary Recurrence in the Patient with Renal-Cancer - Contralateral Kidney and Other Sites. Urologic Clinics of North America 1994;21(4):601-24. Tilgjengelig fra: ISI:A1994PT31600004
  191. Pongracz N, Zimmerman R, Kotz R. Orthopaedic management of bony metastases of renal cancer. Semin Surg Oncol 1988;4(2):139-42. Tilgjengelig fra: PM:3393777
  192. Kasibhatla M, Steinberg P, Meyer J, Ernstoff MS, George DJ. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin Genitourin Cancer 2007;5(4):291-4.
  193. Reichel LM, Pohar S, Heiner J, Buzaianu EM, Damron TA. Radiotherapy to bone has utility in multifocal metastatic renal carcinoma. Clin Orthop Relat Res 2007;459:133-8.
  194. Lee J, Hodgson D, Chow E, Bezjak A, Catton P, Tsuji D, et al. A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer 2005;104(9):1894-900.
  195. Cannady SB, Cavanaugh KA, Lee SY, Bukowski RM, Olencki TE, Stevens GH, et al. Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. Int J Radiat Oncol Biol Phys 2004;58(1):253-8.
  196. Wilson D, Hiller L, Gray L, Grainger M, Stirling A, James N. The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol ) 2003;15(7):400-7.
  197. Juusela H, Malmio K, Alfthan O, Oravisto KJ. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol 1977;11(3):277-81.
  198. Kjaer M, Iversen P, Hvidt V, Bruun E, Skaarup P, Bech HJ, et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 1987;21(4):285-9.
  199. Beitler JJ, Makara D, Silverman P, Lederman G. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol 2004;27(6):646-8.
  200. Wersall PJ, Blomgren H, Lax I, Kalkner KM, Linder C, Lundell G, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005;77(1):88-95.
  201. Svedman C, Sandstrom P, Pisa P, Blomgren H, Lax I, Kalkner KM, et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 2006;45(7):870-5.
  202. Svedman C, Karlsson K, Rutkowska E, Sandstrom P, Blomgren H, Lax I, et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol 2008;47(8):1578-83.
  203. Wersall PJ, Blomgren H, Pisa P, Lax I, Kalkner KM, Svedman C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol 2006;45(4):493-7.
  204. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530-40.
  205. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;(1):CD001425.
  206. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163(2):408-17.
  207. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23(1):133-41.
  208. McDermott DF, Ghebremichael M, Signoretti S, Margolin KA, Clark J, Sosman JA, et al. The high-dose aldesleukin (HD IL-2) Select trial in patients with metastatic renal cell carcinoma (mRCC): Preliminary assessment of clinical benefit. ASCO GU Cancers Symposium Proceedings Book 2010;(#321)
  209. Donskov F. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. Dan Med Bull 2007;54(4):249-65.
  210. Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010;375(9715):641-8.
  211. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34. Tilgjengelig fra: PM:17215530
  212. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-8. Tilgjengelig fra: PM:19451442
  213. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(8):1280-9.
  214. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Jr., et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010;116(5):1272-80.
  215. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295(21):2516-24. Tilgjengelig fra: PM:16757724
  216. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24.
  217. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90. Tilgjengelig fra: PM:19487381
  218. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8.
  219. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34. Tilgjengelig fra: PM:12890841
  220. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25(29):4536-41.
  221. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11. Tilgjengelig fra: PM:18156031
  222. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26(33):5422-8.
  223. Escudier BJ, Bellmunt J, Negrier S, Melichar B, Bracarda S, Ravaud A, et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009;27(15S):5020.
  224. Rini BI, Halabi S, Rosenberg J, Stadler WM, Vaena DA, Atkins JN, et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 2009;27(18S):LBA5019.
  225. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81. Tilgjengelig fra: PM:17538086
  226. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56.
  227. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65.
  228. Everolimus for the second-line treatment of advanced renal cell carcinoma. London: National Institute for Health and Clinical Excellence; 2011. NICE technology appraisal guidance 219. Tilgjengelig fra: http://www.nice.org.uk/nicemedia/live/13437/54111/54111.pdf
  229. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101(7):1545-51.
  230. Haas N, Manola J, Pins M, Liu G, McDermott D, Nanus D, et al. ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features. J Clin Oncol 2009;27(15S):5038.
  231. Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol 2007;177(5):1698-702.
  232. Miyake H, Haraguchi T, Takenaka A, Fujisawa M. Metastatic collecting duct carcinoma of the kidney responded to sunitinib. Int J Clin Oncol 2011;16(2):153-5.
  233. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103(9):763-73.
  234. Schwandt A, Wood LS, Rini B, Dreicer R. Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther 2009;2:51-61.
  235. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Cllin Oncol 2008;26(32):5204-12.
  236. Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009;182(1):29-34.
  237. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115(1):61-7.
  238. Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010;116(23):5400-6.
  239. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363(9409):594-9. Tilgjengelig fra: PM:14987883
  240. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(25):4076-81.
  241. Thomas AA, Rini BI, Stephenson AJ, Garcia JA, Fergany A, Krishnamurthi V, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009;182(3):881-6.
  242. Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 2009;115(10 Suppl):2355-60.